Diffuse gliomas present a significant challenge for healthcare systems globally. While brain MRI plays a vital role in diagnosis, prognosis, and treatment monitoring, accurately characterizing gliomas using conventional MRI techniques alone is challenging. In this study, we explored the potential of utilizing the amide proton transfer (APT) technique to predict tumor grade and type based on the WHO 2021 Classification of CNS Tumors.
Methods
Forty-two adult patients with histopathologically confirmed brain gliomas were included in the study. They underwent 3T MRI imaging, which involved APT sequence. Multinomial and binary logistic regression models were employed to classify patients into clinically relevant groups based on MRI findings and demographic variables.
Results
We found that the best model for tumor grade classification included patient age along with APT values. The highest sensitivity (88%) was observed for Grade 4 tumors, while Grade 3 tumors showed the highest specificity (79%). For tumor type classification, our model incorporated four predictors: APT values, patient’s age, necrosis, and the presence of hemorrhage. The glioblastoma group had the highest sensitivity and specificity (87%), whereas balanced accuracy was the lowest for astrocytomas (0.73).
Conclusion
The APT technique shows great potential for noninvasive evaluation of diffuse gliomas. The changes in the classification of gliomas as per the WHO 2021 version of the CNS Tumor Classification did not affect its usefulness in predicting tumor grade or type.
PellerinoACacceseMPadovanM, et al.“Epidemiology, risk factors, and prognostic factors of gliomas. Clin Transl Imaging2022; 10(5): 467–475. DOI: 10.1007/S40336-022-00489-6/METRICS
2.
HorbinskiCNaborsLBPortnowJ, et al.NCCN Guidelines® insights: central nervous system cancers, version 2.2022: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw2023; 21(1): 12–20. DOI: 10.6004/JNCCN.2023.0002
3.
PowterBJeffreysSASareenH, et al.Human TERT promoter mutations as a prognostic biomarker in glioma. J Cancer Res Clin Oncol2021; 147(4): 1007–1017. DOI: 10.1007/S00432-021-03536-3/TABLES/2
4.
WengerACarénH. “Methylation profiling in diffuse gliomas: diagnostic value and considerations”. Cancers2022; 14(22): 5679. DOI: 10.3390/CANCERS14225679
5.
LouisDNPerryAWesselingP, et al.The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol2021; 23(8): 1231–1251. DOI: 10.1093/NEUONC/NOAB106
6.
KerJBaiYLeeHY, et al.Automated brain histology classification using machine learning. J Clin Neurosci2019; 66: 239–245. DOI: 10.1016/j.jocn.2019.05.019
7.
IdeguchiMBaiYLeeHY, et al.Investigation of histological heterogeneity based on the discrepancy between the hyperintense area on T2-weighted images and the accumulation area on 11C-methionine PET in minimally enhancing glioma. Interdisciplinary Neurosurgery2022; 27: 101364. DOI: 10.1016/J.INAT.2021.101364
8.
NielsenLAGBangsøJALindahlKH, et al.Evaluation of the proliferation marker Ki-67 in gliomas: interobserver variability and digital quantification. Diagn Pathol2018; 13(1): 38. DOI: 10.1186/S13000-018-0711-2
9.
WangXWangRYangS, et al.Combining radiology and pathology for automatic glioma classification. Front Bioeng Biotechnol2022; 10: 841958. DOI: 10.3389/FBIOE.2022.841958/BIBTEX
10.
TebhaSSAli MemonSMehmoodQ, et al.Glioblastoma management in low and middle-income countries; existing challenges and policy recommendations. Brain and Spine2023; 3: 101775. DOI: 10.1016/J.BAS.2023.101775
11.
UpadhyayNWaldmanAD. Conventional MRI evaluation of gliomas. Br J Radiol2011; 84(Spec Iss 2): S107. DOI: 10.1259/BJR/65711810
12.
GeminiLTortoraMGiordanoP, et al.Vasari scoring system in discerning between different degrees of glioma and IDH status prediction: a possible machine learning application?J Imaging2023; 9(4): 75. DOI: 10.3390/JIMAGING9040075
13.
YouWMaoYJiaoX, et al.The combination of radiomics features and VASARI standard to predict glioma grade. Front Oncol2023; 13: 1083216. DOI: 10.3389/FONC.2023.1083216/BIBTEX
14.
LiYAmmariSLawranceL, et al.Radiomics-based method for predicting the glioma subtype as defined by tumor grade, IDH mutation, and 1p/19q codeletion. Cancers2022; 14(7): 1778. DOI: 10.3390/CANCERS14071778
15.
WenZHuSHuangF, et al.MR imaging of high-grade brain tumors using endogenous protein and peptide-based contrast. Neuroimage2010; 51(2): 616–622. DOI: 10.1016/J.NEUROIMAGE.2010.02.050
16.
JonesCKSchlosserMJVan ZijlPCM, et al.Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med2006; 56(3): 585–592. DOI: 10.1002/MRM.20989
17.
SotiriosBDemetriouETopriceanuCC, et al.The role of APT imaging in gliomas grading: a systematic review and meta-analysis. Eur J Radiol2020; 133: 109353. DOI: 10.1016/J.EJRAD.2020.109353
18.
JiangSEberhartECGZhangY, et al.Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas. Eur J Cancer2017; 83: 9–18. DOI: 10.1016/J.EJCA.2017.06.009
19.
ZhouJHeoHYKnutssonL, et al.APT-weighted MRI: techniques, current neuro applications, and challenging issues2019. J Magn Reson Imag; 50(2): 347–364. DOI: 10.1002/JMRI.26645
20.
FriismoseAIMarkovicLNguyenN, et al.Amide proton transfer-weighted MRI in the clinical setting – correlation with dynamic susceptibility contrast perfusion in the post-treatment imaging of adult glioma patients at 3T. Radiography2022; 28(1): 95–101. DOI: 10.1016/J.RADI.2021.08.006
21.
KangXWXiYBLiuTT, et al.Grading of Glioma: combined diagnostic value of amide proton transfer weighted, arterial spin labeling and diffusion weighted magnetic resonance imaging. BMC Med Imag2020; 20(1): 1–8. DOI: 10.1186/S12880-020-00450-X/FIGURES/2
22.
NakajoMBoharaMKamimuraK, et al.Correlation between amide proton transfer-related signal intensity and diffusion and perfusion magnetic resonance imaging parameters in high-grade glioma. Sci Rep2021; 11(1): 1–7. DOI: 10.1038/s41598-021-90841-z
23.
BaiYLinYZhangW, et al.Noninvasive amide proton transfer magnetic resonance imaging in evaluating the grading and cellularity of gliomas. Oncotarget2017; 8(4): 5834–5842. DOI: 10.18632/ONCOTARGET.13970
24.
XuZKeCLiuJ, et al.Diagnostic performance between MR amide proton transfer (APT) and diffusion kurtosis imaging (DKI) in glioma grading and IDH mutation status prediction at 3 T. Eur J Radiol2021; 134(Jan): 109466. DOI: 10.1016/J.EJRAD.2020.109466
25.
GuoHLiuJHuJ, et al.Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion-weighted MRI models. J Magn Reson Imag2022; 56(6): 1834–1844. DOI: 10.1002/JMRI.28211
26.
JooBHanKAhnSS, et al.Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma. Eur Radiol2019; 29(12): 6643. DOI: 10.1007/S00330-019-06203-X
27.
ChenKJiangXWDengLJ, et al.Differentiation between glioma recurrence and treatment effects using amide proton transfer imaging: a mini-Bayesian bivariate meta-analysis. Front Oncol2022; 12: 852076. DOI: 10.3389/FONC.2022.852076/BIBTEX
28.
von Knebel DoeberitzNKrohFBreitlingJ, et al.CEST imaging of the APT and ssMT predict the overall survival of patients with glioma at the first follow-up after completion of radiotherapy at 3T. Radiother Oncol2023; 184: 109694. DOI: 10.1016/J.RADONC.2023.109694
29.
WillmsKChadhaSvon ReppertM, et al.NIMG-59. Radiomic feature cluster analysis of idh-mutant glioma subtypes. Neuro Oncol2023; 25(Supplement_5): v199. DOI: 10.1093/NEUONC/NOAD179.0755
30.
RenJZhaiXYinH, et al.Multimodality MRI radiomics based on machine learning for identifying true tumor recurrence and treatment-related effects in patients with postoperative glioma. Neurol Ther2023; 12(5): 1729–1743. DOI: 10.1007/S40120-023-00524-2/FIGURES/5
31.
SalariNFatahianRKazeminiaM, et al.Patients’ survival with astrocytoma after treatment: a systematic review and meta-analysis of clinical trial studies. Indian J Surg Oncol2022; 13(2): 35. DOI: 10.1007/S13193-022-01533-7
32.
MarraJSMendesGPYoshinariGH, et al.Survival after radiation therapy for high-grade glioma. Rep Practical Oncol Radiother2019; 24(1): 35–40. DOI: 10.1016/J.RPOR.2018.09.003
33.
YeboaDNYuJBLiaoE, et al.Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas. Clin Transl Radiat Oncol2019; 15: 46–52. DOI: 10.1016/J.CTRO.2018.12.003
34.
HanYWangWYangY, et al.Amide proton transfer imaging in predicting isocitrate dehydrogenase 1 mutation status of grade II/III gliomas based on support vector machine. Front Neurosci2020; 14: 510647. DOI: 10.3389/FNINS.2020.00144/BIBTEX
35.
SuCXuSLinD, et al.Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients. Eur Radiol2022; 32(1): 101–111. DOI: 10.1007/S00330-021-08175-3/METRICS
36.
QuSQiuOHuZ. The prognostic factors and nomogram for patients with high-grade gliomas. Fundamental Research2021; 1(6): 824–828. DOI: 10.1016/J.FMRE.2021.07.005
37.
JiaZLiXYanY, et al.Exploring the relationship between age and prognosis in glioma: rethinking current age stratification. BMC Neurol2022; 22(1): 74–88. DOI: 10.1186/S12883-022-02879-9
38.
LinZYangRLiK, et al.Establishment of age group classification for risk stratification in glioma patients. BMC Neurol2020; 20(1): 310. DOI: 10.1186/S12883-020-01888-W
39.
SuCLiuCZhaoL, et al.Amide proton transfer imaging allows detection of glioma grades and tumor proliferation: comparison with ki-67 expression and proton MR spectroscopy imaging. AJNR Am J Neuroradiol2017; 38(9): 1702. DOI: 10.3174/AJNR.A5301
40.
TogaoOYoshiuraTKeuppJ, et al.Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. Neuro Oncol2014; 16(3): 441. DOI: 10.1093/NEUONC/NOT158
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
